Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Transgene and NEC expect to present additional immunological and clinical data from the Phase I trial at a scientific conference in the first half of 2024.
- Transgene and NEC expect to present additional immunological and clinical data from the Phase I trial at a scientific conference in the first half of 2024.
- We are looking forward to continuing to treat patients with our individualized cancer vaccine TG4050.
- Masamitsu Kitase, Corporate SVP, Head of Healthcare and Life Sciences Division, NEC Corporation, commented: "Transgene has been our trusted partner in developing our joint neoantigen asset TG4050.
- *Ottensmeier et al., "Safety and Immunogenicity of TG4050: a personalized cancer vaccine in head and neck carcinoma" ASCO 2023, June 6, 2023, Poster presentation